{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:25:13Z","timestamp":1765974313432,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jaad.2015.06.004","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T08:12:02Z","timestamp":1436861522000},"page":"420-428.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis"],"prefix":"10.1016","volume":"73","author":[{"given":"Christine S.","family":"Ahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily H.","family":"Dothard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Garner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.06.004_bib1","first-page":"917","article-title":"Trends in systemic psoriasis treatment therapies from 1993 through 2010","volume":"13","author":"Shaw","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2015.06.004_bib2","unstructured":"FDA. What's new for biologics. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/NewsEvents\/WhatsNewforBiologics\/default.htm. Accessed September 12, 2014."},{"issue":"1","key":"10.1016\/j.jaad.2015.06.004_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaad.2013.08.049","article-title":"From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis","volume":"70","author":"Motaparthi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2015.06.004_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/1346-8138.12239","article-title":"Japanese guidance for use of biologics for psoriasis (the 2013 version)","volume":"40","author":"Ohtsuki","year":"2013","journal-title":"J Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2015.06.004_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.004_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2015.06.004_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists' guidelines for biologic interventions for psoriasis","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2015.06.004_bib8","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1468-3083.2009.03166.x","article-title":"A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: \u2018AGREE-ing\u2019 on a common base for European evidence-based psoriasis treatment guidelines","volume":"23","author":"Nast","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2015.06.004_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2015.06.004_bib10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2015.06.004_bib11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jaad.2008.03.004","article-title":"To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis","volume":"58","author":"Huang","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2015.06.004_bib12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1468-3083.2010.03836.x","article-title":"Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients","volume":"25","author":"S\u00e1nchez-Moya","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2015.06.004_bib13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2133.2009.09331.x","article-title":"Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test","volume":"161","author":"Laffitte","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2015.06.004_bib14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1365-2133.2008.08457.x","article-title":"QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy","volume":"158","author":"Desai","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2015.06.004_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12016-012-8301-7","article-title":"Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring","volume":"44","author":"Sivamani","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.004_bib16","first-page":"553","article-title":"Clinical experience of QuantiFERON(\u00ae) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan","volume":"164","author":"Chiu","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2015.06.004_bib17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jaad.2012.04.036","article-title":"Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management","volume":"67","author":"Abramson","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2015.06.004_bib18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2133.2011.10329.x","article-title":"Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab","volume":"165","author":"van L\u00fcmig","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2015.06.004_bib19","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","article-title":"The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature","volume":"159","author":"Domm","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.004_bib20","first-page":"280","article-title":"Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-a inhibitors","volume":"10","author":"Chen","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2015.06.004_bib21","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/j.1468-3083.2012.04450.x","article-title":"Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry","volume":"27","author":"Gisondi","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2015.06.004_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1590\/abd1806-4841.20132035","article-title":"Evaluation of renal function in patients with psoriasis using immunobiologicals","volume":"88","author":"Melga\u00e7o","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2015.06.004_bib23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2133.2011.10555.x","article-title":"Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction","volume":"165","author":"Hoffmann","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.06.004_bib24","doi-asserted-by":"crossref","first-page":"352686","DOI":"10.1155\/2011\/352686","article-title":"Infliximab induces increase in triglyceride levels in psoriatic arthritis patients","volume":"2011","author":"Castro","year":"2011","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"10.1016\/j.jaad.2015.06.004_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1440-0960.2011.00853.x","article-title":"The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis","volume":"53","author":"Young","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2015.06.004_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2015.06.004_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-3083.2010.03754.x","article-title":"Safety of anti-tumour necrosis factor-\u03b1 agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature","volume":"25","author":"Fotiadou","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2015.06.004_bib28","first-page":"285","article-title":"Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease","volume":"25","author":"Cassano","year":"2011","journal-title":"J Biol Regul Homeost Agents"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.004_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1346-8138.2011.01434.x","article-title":"Use of anti-tumor necrosis factor-\u03b1 therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan","volume":"39","author":"Cho","year":"2012","journal-title":"J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.004_bib30","first-page":"645","article-title":"Tumour necrosis factor-\u03b1 antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients","volume":"164","author":"Prignano","year":"2011","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2015.06.004_bib31","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1365-2133.2010.09714.x","article-title":"Safety of antitumour necrosis factor-\u03b1 therapy in psoriatic patients with hepatitis B virus infection","volume":"162","author":"Nosotti","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.06.004_bib32","doi-asserted-by":"crossref","first-page":"410521","DOI":"10.1155\/2013\/410521","article-title":"Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients","volume":"2013","author":"Laurenti","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.004_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br J Dermatol"},{"issue":"44","key":"10.1016\/j.jaad.2015.06.004_bib34","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.3748\/wjg.v19.i44.7867","article-title":"Tumor necrosis factor-\u03b1 inhibitors and chronic hepatitis C: a comprehensive literature review","volume":"19","author":"Pompili","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jaad.2015.06.004_bib35","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaad.2009.07.010","article-title":"Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data","volume":"62","author":"Paradisi","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2015.06.004_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/120347541201600305","article-title":"Biologic therapy in psoriasis: perspectives on associated risks and patient management","volume":"16","author":"Papp","year":"2012","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2015.06.004_bib37","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/0168-8278(90)90177-S","article-title":"Alpha-interferon treatment in Chinese patients with chronic hepatitis B","volume":"11","author":"Lok","year":"1990","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jaad.2015.06.004_bib38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.jaad.2015.06.004_bib39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.hlc.2012.12.002","article-title":"Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure","volume":"22","author":"Javed","year":"2013","journal-title":"Heart Lung Circ"},{"issue":"2","key":"10.1016\/j.jaad.2015.06.004_bib40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2011.07.040","article-title":"Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis","volume":"67","author":"Pariser","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2015.06.004_bib41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215017430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215017430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:35:40Z","timestamp":1759271740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215017430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0190962215017430"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.06.004","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}